Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer
Author:
Funder
Uniformed Services University of the Health Sciences
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-020-05884-z.pdf
Reference70 articles.
1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389
2. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434. https://doi.org/10.1158/1078-0432.ccr-06-3045
3. Reddy SM, Barcenas CH, Sinha AK et al (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118(1):17–23. https://doi.org/10.1038/bjc.2017.379
4. National Comprehensive Cancer Network Breast Cancer (Version 3.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
5. Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer;EMBO Molecular Medicine;2024-03-13
2. Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer;Annals of Palliative Medicine;2021-11
3. Ovarian Cancer Risk Scores Based on Immune-Related Pseudogenes to Predict Overall Survival and Guide Immunotherapy and Chemotherapy;Evidence-Based Complementary and Alternative Medicine;2021-10-08
4. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells;Cancer Treatment and Research Communications;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3